Hansen L (2003). “Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia”. J. Psychopharmacol. (Oxford)17 (4): 451-2. doi:10.1177/0269881103174003. PMID14870959.
Lerner V, Bergman J, Statsenko N, Miodownik C (2004). “Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study”. The Journal of clinical psychiatry65 (11): 1550-4. doi:10.4088/JCP.v65n1118. PMID15554771.
Berk, Michael; Copolo, David; Dean, Olivia; Lu, Kristy; Jeavons, Sue; Schapkaitz, Ian; Anderson-Hunt, Murray; Judd, Fiona et al. (September 2008). “N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial”. Biological Psychiatry64 (5): 361–368. doi:10.1016/j.biopsych.2008.03.004. PMID18436195.
“Managing antipsychotic-induced acute and chronic akathisia”. Drug Safety : an International Journal of Medical Toxicology and Drug Experience (1): 73–81. (January 2000). PMID10647977.
Hansen L (2003). “Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia”. J. Psychopharmacol. (Oxford)17 (4): 451-2. doi:10.1177/0269881103174003. PMID14870959.
Lerner V, Bergman J, Statsenko N, Miodownik C (2004). “Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study”. The Journal of clinical psychiatry65 (11): 1550-4. doi:10.4088/JCP.v65n1118. PMID15554771.
Berk, Michael; Copolo, David; Dean, Olivia; Lu, Kristy; Jeavons, Sue; Schapkaitz, Ian; Anderson-Hunt, Murray; Judd, Fiona et al. (September 2008). “N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial”. Biological Psychiatry64 (5): 361–368. doi:10.1016/j.biopsych.2008.03.004. PMID18436195.